vasamed Announces New Financing as Well as Conversion of Debt to Capital Stock by Circle F MINNEAPOLIS, May 12 /PRNewswire-FirstCall/ -- vasamed (OTC:OPTL) (BULLETIN BOARD: OPTL) , a leader in non-invasive, hemodynamic assessment technology, announced that it secured $750,000 of new financing concomitant with Circle F Ventures, LLC and affiliates converting cash advances, outstanding interest and fees and expenses in the amount of $6,001,849.30, into shares of Series C preferred stock. To complete the transactions, vasamed issued 75,020 shares of the company's Series C preferred stock at a purchase price of $90.00 per share. Each share of Series C preferred stock is convertible into 40 shares of common stock at a conversion price of $2.25 per share. As a result of the conversions, Circle F and its affiliates now beneficially own 6,488,972 shares of vasamed's common stock on an as converted basis representing a 72.4% ownership interest in the company. Paulita LaPlante, President and CEO of vasamed, said, "We are pleased with this new financing and with Circle F's continued confidence in vasamed. These new monies and the further investment by Circle F will be used to support the launch of our AcQtrac(TM) Impedance Cardiography System, a non invasive hemodynamic monitor for the doctor's office setting, as we gear up to support Medical Sales Partners and their full-service, nationwide team in the introduction and distribution of AcQtrac ICG to the cardiology marketplace." vasamed(TM) designs, licenses, manufactures and distributes products that can be used by your doctor -- right in the office -- to tell him/her whether your heart and blood vessels are healthy. vasamed's products and technology include SensiLase(TM) Microvascular Assessment System to measure Skin Perfusion Pressure (SPP), AcQtrac(TM) Impedance Cardiography (ICG) to monitor heart function and Tissue Carbon Dioxide Technologies, including CapnoProbe(TM), to monitor tissue wellness. For more information about vasamed technology and services and new products, please call (800) 695.2737 or see the company's web site at http://www.vasamed.com/ . Medical Sales Partners provides customer focused solutions to the cardiovascular market through their relationships with GE, Philips, Schiller, Welch Allyn and Heartlabs. Medical Sales Partners sales consultants are dedicated to the cardiology market for hospitals and medical practices nationwide. For more information on Medical Sales Partners, Inc., please call 866.394.3939 or visit the company online at http://www.medicalsalespartners.com/ . DATASOURCE: vasamed CONTACT: Wes Peterson, CFO of vasamed, +1-952-944-5857 ext. 542 Web site: http://www.vasamed.com/ http://www.medicalsalespartners.com/

Copyright